Efficacy and Safety of Etoricoxib-tramadol Tablet in Acute Postoperative Pain

Efficacy and Safety of Etoricoxib-tramadol 120mg/100mg on Acute Pain After Impacted Lower Third Molar Extraction: A Double Blind Randomized Controlled Trial

The goal of the present phase IIb clinical trial was to compare the safety and efficacy of the fixed-dose combination etoricoxib-tramadol 120mg/100mg tablet (once a day, for three days) versus naproxen 220mg tablet plus tramadol 50 mg capsule in patients with acute postoperative pain after impacted third molar extraction. The main research question was: Is the analgesic efficacy of etoricoxib-tramadol 120mg/100mg tablet non-inferior to naproxen 220 mg tablet + tramadol 50 mg capsule in a clinical model of moderate to severe acute pain? After informed consent, patients were randomly assigned to one of the two arms: test product (etoricoxib-tramadol 120mg/100mg tablet) or active comparator (naproxen 220mg tablet + tramadol 50 mg capsule). After surgery, patients were requested to start the treatment with study drugs (test product was administered once daily for three days; meanwhile reference drug was administered twice a day for three days).

Investigators compared the effects of both treatments on pain intensity at different time frames using the visual analogue scale. Furthermore, the safety of investigational drugs was assessed during the study.

Study Overview

• Status: Completed
• Conditions: Postoperative Pain; Acute Pain
• Intervention / Treatment: Drug: etoricoxib-tramadol; Drug: Naproxen; Drug: Tramadol

• Study Type: Interventional
• Enrollment (Actual): 58
• Phase: Phase 2

Contacts and Locations

Study Locations

• Mexico
  • Oaxaca, Mexico, 68000
    • Oaxaca Site Management Organization

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Patients of both sexes aged from 18 to 40 years.
• Patients who agreed to participate in the study by signing the informed consent.
• Patients with indication for surgical extraction of impacted lower third molars according to the Pell and Gregory classification.
• Healthy subjects or with history of controlled chronic non-communicable diseases or that can be controlled prior to surgery, which, in the investigator's opinion, do not represent an additional risk for the patient.
• Patients who, at the investigator's discretion, meet personal and family conditions that allow them to properly comply with the activities described in the protocol and adherence to treatment.

Exclusion Criteria:

• Findings in the clinical history, vital signs, physical examination or laboratory studies suggesting abnormal conditions which represent a risk for subject's health at the investigator´s discretion.
• Hypersensitivity to any of the active ingredients and/or excipients of the investigational drugs.
• Patients with active peptic or gastroduodenal ulcer or diagnosis 30 days prior to signing the informed consent.
• Patients with history of allergic asthma reactions.
• Patients with severe hepatic dysfunction, classified as Child Pugh C or when being less, the investigator considers it an additional risk for patients.
• Patients with a creatinine clearance <30 mL/min.
• Patients with coagulation disorders.
• Patients with Systemic Lupus Erythematosus.
• Patients with congestive heart failure (NYHA class II-IV), ischemic heart disease, peripheral arterial disease, or cerebrovascular disease who have recently (3 months) undergone coronary artery bypass grafting or angioplasty procedures.
• Patients at high risk of acute cardiovascular events (intense smoking, hypertension or uncontrolled diabetes mellitus).
• Patients with a history of systemic neoplastic diseases or under treatment with chemotherapy.
• Patients with a history of illicit drug abuse or addiction to alcohol or tobacco.
• Patients with monoamine oxidase inhibitors (MAOIs) treatment or during the last 2 weeks prior to the study drug administration.
• Patients with opioid analgesics, neuromodulators, or long-acting NSAIDs therapy who, according to medical criteria, cannot carry out a withdrawal scheme for at least five half-lives prior to surgery.
• Patients with history of seizures or who are under treatment with medications that reduce the seizure threshold and who, according to medical criteria, cannot carry out a withdrawal scheme within 30 days prior to surgery.
• Positive pregnancy test or lactating women.
• Positive rapid urine drug test.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Etoricoxib-Tramadol; Etoricoxib-Tramadol 120mg/100mg tablet, once-daily, for 3 days	Drug: etoricoxib-tramadol; Oral administration (with or without food)
Active Comparator: Naproxen + Tramadol; Naproxen 220 mg tablet + Tramadol 50 mg capsule, twice a day, for 3 days.	Drug: Naproxen; Oral administration (with or without food); Drug: Tramadol; Oral administration (with or without food)

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pain intensity difference (PID)	The difference in pain intensity at 4 h after drug administration versus time 0 (baseline, before dosing)	At 4 h (Day 0, postdosing) respect the baseline (Day 0, before dosing)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Pain intensity difference (PID)	The difference in pain intensity at 1, 2, 3, 6, 12, 24, 48, and 72 hours after drug administration versus time 0 (baseline, before dosing)	At 1, 2, 3, 6, 12, 24, 48, and 72 hours postdosing respecto the baseline (Day 0, before dosing)
Total pain relief (TOTPAR)	TOTPAR is a time-weighted measure of AUC or total area under the pain relief curve and is a summary measure that integrates serial assessments of a subject's pain over the duration of the study or in any time frime.	At 4, 6, 12, 24, 48, 72 hours postdosing respect to the baseline (Day 0, before dosing)
Trismus control	Measurement the difference of mouth opening (in mm) at baseline (before dosing) and at the end of the study (Day 7).	At the end of the study (Day 7) respect to the baseline (Day 0, before dosing)
Adverse events	Characteristics and frequency of adverse events	From informed consent (Day -28) to the end of the study (Day 7)

Collaborators and Investigators

• Sponsor: Laboratorios Liomont
• Collaborators: Infinite Clinical Research, S.A. de C.V.
• Investigators: Principal Investigator: Tania A. Sibaja Ponce, M.D., Oaxaca Site Management Organization, S.C.

Study record dates

Study Major Dates

• Study Start (Actual): September 29, 2021
• Primary Completion (Actual): August 18, 2022
• Study Completion (Actual): October 14, 2022

Study Registration Dates

• First Submitted: August 1, 2023
• First Submitted That Met QC Criteria: August 10, 2023
• First Posted (Actual): August 16, 2023

Study Record Updates

• Last Update Posted (Actual): October 10, 2024
• Last Update Submitted That Met QC Criteria: October 8, 2024
• Last Verified: October 1, 2024

More Information

Terms related to this study

• Keywords: Analgesia; Third molar extraction; Etoricoxib-tramadol
• Additional Relevant MeSH Terms: Pathologic Processes; Postoperative Complications; Pain; Neurologic Manifestations; Pain, Postoperative; Acute Pain; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Central Nervous System Depressants; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Cyclooxygenase Inhibitors; Analgesics, Opioid; Narcotics; Cyclooxygenase 2 Inhibitors; Gout Suppressants; Tramadol; Naproxen; Etoricoxib
• Other Study ID Numbers: LT-04-20 (Other Identifier: COFEPRIS, Mexico)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No